Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
309495
European Research Council - International
PubMed
30925288
DOI
10.1016/j.biomaterials.2019.03.025
PII: S0142-9612(19)30169-3
Knihovny.cz E-resources
- Keywords
- Liposomes, Liver fibrosis, Macrophages, Microbubbles, Nanomedicine, Polymers, Targeted delivery,
- MeSH
- Microscopy, Fluorescence MeSH
- Immunohistochemistry MeSH
- Liver Cirrhosis metabolism MeSH
- Drug Delivery Systems MeSH
- Liposomes chemistry MeSH
- Lymphocytes metabolism MeSH
- Macrophages metabolism MeSH
- Microbubbles MeSH
- Mice MeSH
- Nanomedicine MeSH
- Polymers chemistry MeSH
- Flow Cytometry MeSH
- X-Ray Microtomography MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Liposomes MeSH
- Polymers MeSH
Myeloid immune cells promote inflammation and fibrosis in chronic liver diseases. Drug delivery systems, such as polymers, liposomes and microbubbles, efficiently target myeloid cells in healthy liver, but their targeting properties in hepatic fibrosis remain elusive. We therefore studied the biodistribution of three intravenously injected carrier material, i.e. 10 nm poly(N-(2-hydroxypropyl)methacrylamide) polymers, 100 nm PEGylated liposomes and 2000 nm poly(butyl cyanoacrylate) microbubbles, in two fibrosis models in immunocompetent mice. While whole-body imaging confirmed preferential hepatic uptake even after induction of liver fibrosis, flow cytometry and immunofluorescence analysis revealed markedly decreased carrier uptake by liver macrophage subsets in fibrosis, particularly for microbubbles and polymers. Importantly, carrier uptake co-localized with immune infiltrates in fibrotic livers, corroborating the intrinsic ability of the carriers to target myeloid cells in areas of inflammation. Of the tested carrier systems liposomes had the highest uptake efficiency among hepatic myeloid cells, but the lowest specificity for cellular subsets. Hepatic fibrosis affected carrier uptake in liver and partially in spleen, but not in other tissues (blood, bone marrow, lung, kidney). In conclusion, while drug carrier systems target distinct myeloid cell populations in diseased and healthy livers, hepatic fibrosis profoundly affects their targeting efficiency, supporting the need to adapt nanomedicine-based approaches in chronic liver disease.
References provided by Crossref.org